泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301263 泰恩康

交易中 06-17 13:16:39

{"stockData":{"symbol":"301263","market":"SZ","secType":"STK","nameCN":"泰恩康","latestPrice":12.79,"timestamp":1718601399000,"preClose":12.91,"halted":0,"volume":715740,"delay":0,"floatShares":268000000,"shares":425000000,"eps":0.3612,"marketStatus":"交易中","marketStatusCode":2,"change":-0.12,"latestTime":"06-17 13:16:39","open":12.91,"high":12.99,"low":12.7,"amount":9199600,"amplitude":0.0225,"askPrice":12.81,"askSize":1,"bidPrice":12.79,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.3612,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1718607600000},"adr":0,"adjPreClose":12.91,"symbolType":"stock","openAndCloseTimeList":[[1718587800000,1718595000000],[1718600400000,1718607600000]],"highLimit":14.2,"lowLimit":11.62,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":425497500,"pbRate":2.99,"roa":"--","roe":"2.51%","epsLYR":0.38,"committee":0.710692,"marketValue":5442000000,"floatMarketCap":3424000000,"peRate":35.409745,"changeRate":-0.0093,"turnoverRate":0.0027,"status":1},"requestUrl":"/m/hq/s/301263/tweets","defaultTab":"tweets","newsList":[{"id":"2443564612","title":"泰恩康6月14日现1笔大宗交易 成交金额663.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2443564612","media":"智能小浪","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443564612?lang=zh_cn&edition=full","pubTime":"2024-06-14 17:00","pubTimestamp":1718355600,"startTime":"0","endTime":"0","summary":"　　6月14日，泰恩康收跌1.15%，收盘价为12.91元，发生1笔大宗交易，合计成交量63.4万股，成交金额663.16万元。　　进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为1.1亿元。该股近5个交易日累计上涨2.30%，主力资金合计净流出128.52万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-06-14/doc-inayszph2853198.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-06-14/doc-inayszph2853198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2443564310","title":"6月14日泰恩康现1笔折价18.98%的大宗交易 合计成交663.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2443564310","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443564310?lang=zh_cn&edition=full","pubTime":"2024-06-14 16:40","pubTimestamp":1718354419,"startTime":"0","endTime":"0","summary":"证券之星消息，6月14日泰恩康发生大宗交易，交易数据如下：大宗交易成交价格10.46元，相对当日收盘价折价18.98%，成交63.4万股，成交金额663.16万元，买方营业部为中国银河证券股份有限公司汕头澄海证券营业部，卖方营业部为西南证券股份有限公司重庆奉节永安路证券营业部。近三个月该股共发生7笔大宗交易，合计成交9.28万手，折价成交7笔。截至2024年6月14日收盘，泰恩康报收于12.91元，下跌1.15%，换手率0.5%，成交量1.35万手，成交额1742.93万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061400030591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2442743352","title":"泰恩康6月11日现1笔大宗交易 成交金额2082万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442743352","media":"智能小浪","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442743352?lang=zh_cn&edition=full","pubTime":"2024-06-11 17:00","pubTimestamp":1718096400,"startTime":"0","endTime":"0","summary":"　　6月11日，泰恩康收涨2.62%，收盘价为13.33元，发生1笔大宗交易，合计成交量200万股，成交金额2082万元。　　进一步统计，近3个月内该股累计发生5笔大宗交易，合计成交金额为9451.2万元。该股近5个交易日累计下跌0.97%，主力资金合计净流入1090.21万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-06-11/doc-inaykeaa3914223.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-06-11/doc-inaykeaa3914223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2442351558","title":"6月11日泰恩康现1笔折价21.91%的大宗交易 合计成交2082万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442351558","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442351558?lang=zh_cn&edition=full","pubTime":"2024-06-11 16:34","pubTimestamp":1718094851,"startTime":"0","endTime":"0","summary":"证券之星消息，6月11日泰恩康发生大宗交易，交易数据如下：大宗交易成交价格10.41元，相对当日收盘价折价21.91%，成交200万股，成交金额2082万元，买方营业部为中国银河证券股份有限公司汕头澄海证券营业部，卖方营业部为西南证券股份有限公司重庆奉节永安路证券营业部。近三个月该股共发生5笔大宗交易，合计成交7.8万手，折价成交5笔。截至2024年6月11日收盘，泰恩康报收于13.33元，上涨2.62%，换手率1.0%，成交量2.67万手，成交额3518.81万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061100019772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2441403745","title":"泰恩康(301263.SZ)董事李挺累计增持20.96万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2441403745","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441403745?lang=zh_cn&edition=full","pubTime":"2024-06-07 17:21","pubTimestamp":1717752068,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司董事、董事会秘书、副总经理李挺通过深圳证券交易所系统集中竞价方式累计增持公司股份20.96万股，占公司当前剔除回购股份后的总股本的0.05%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1132766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2441223770","title":"泰恩康：上述产品为肿瘤药高级医药中间体","url":"https://stock-news.laohu8.com/highlight/detail?id=2441223770","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441223770?lang=zh_cn&edition=full","pubTime":"2024-06-05 18:01","pubTimestamp":1717581683,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康(301263)06月05日在投资者关系平台上答复投资者关心的问题。投资者：四川泰恩康作为泰恩康股份公司下属的原料药生产基地，2024年4月24日，公司第一个800多万的订单正式开机投料，经过近30个昼夜的奋战，按时为客户交付了合格的产品，首战告捷。请问上述800万的产品是什么产品？泰恩康董秘：投资者您好，上述产品为肿瘤药高级医药中间体，感谢您的关注。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060500036353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK1515","BK0250","09939","301263","159938"],"gpt_icon":0},{"id":"2438344485","title":"5月28日泰恩康现1笔折价18.9%的大宗交易 合计成交1798.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2438344485","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438344485?lang=zh_cn&edition=full","pubTime":"2024-05-28 16:42","pubTimestamp":1716885726,"startTime":"0","endTime":"0","summary":"证券之星消息，5月28日泰恩康发生大宗交易，交易数据如下：大宗交易成交价格11.24元，相对当日收盘价折价18.9%，成交160万股，成交金额1798.4万元，买方营业部为中国银河证券股份有限公司汕头澄海证券营业部，卖方营业部为西南证券股份有限公司重庆奉节永安路证券营业部。近三个月该股共发生7笔大宗交易，合计成交11.75万手，折价成交7笔。截至2024年5月28日收盘，泰恩康报收于13.86元，下跌1.28%，换手率0.54%，成交量1.44万手，成交额2002.19万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052800029886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2438803957","title":"泰恩康(301263.SZ)获得孟鲁司特钠颗粒药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2438803957","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438803957?lang=zh_cn&edition=full","pubTime":"2024-05-27 16:41","pubTimestamp":1716799297,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局(简称“国家药监局”)签发的孟鲁司特钠颗粒《药品注册证书》。据悉，孟鲁司特钠颗粒适用于1岁以上儿童哮喘的预防和长期治疗，包括预防白天和夜间的哮喘症状，治疗对阿司匹林敏感的哮喘患者以及预防运动诱发的支气管收缩，减轻过敏性鼻炎引起的症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2437049689","title":"泰恩康最新公告：全资子公司获得甲磺酸雷沙吉兰片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2437049689","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437049689?lang=zh_cn&edition=full","pubTime":"2024-05-21 16:31","pubTimestamp":1716280269,"startTime":"0","endTime":"0","summary":"泰恩康公告，全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局签发的甲磺酸雷沙吉兰片《药品注册证书》。甲磺酸雷沙吉兰片是目前国际上常用的抗帕金森病药物，具有选择性的第二代不可逆单胺氧化酶（MAO-B）抑制剂，雷沙吉兰通过与MAO-B不可逆地结合，阻止脑中多巴胺的分解，增加突触间隙多巴胺的水平，从而有效控制帕金森病的症状。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052100026977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2437897496","title":"泰恩康最新公告：全资子公司获得枸橼酸西地那非口崩片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2437897496","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437897496?lang=zh_cn&edition=full","pubTime":"2024-05-21 16:30","pubTimestamp":1716280219,"startTime":"0","endTime":"0","summary":"泰恩康公告，全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局签发的枸橼酸西地那非口崩片《药品注册证书》。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052100026979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2437689495","title":"泰恩康(301263.SZ)获得两项药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2437689495","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437689495?lang=zh_cn&edition=full","pubTime":"2024-05-21 16:26","pubTimestamp":1716280019,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康 发布公告，公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局签发的枸橼酸西地那非口崩片《药品注册证书》。枸橼酸西地那非口崩片为美国辉瑞公司开发的西地那非迭代剂型，2019年在中国批准进口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1123825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2435687805","title":"泰恩康(301263.SZ)拟10股派3元 于5月23日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2435687805","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435687805?lang=zh_cn&edition=full","pubTime":"2024-05-15 17:46","pubTimestamp":1715766373,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司2023年年度权益分派拟：向全体股东每10股派发现金红利3元(含税)。除权除息日为：2024年5月23日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2434054833","title":"泰恩康(301263.SZ)：利多卡因丙胺卡因气雾剂药品注册临床试验获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2434054833","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434054833?lang=zh_cn&edition=full","pubTime":"2024-05-10 17:40","pubTimestamp":1715334011,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局签发的境内生产药品注册临床试验《受理通知书》，药品名称为：利多卡因丙胺卡因气雾剂。公告称，利多卡因丙胺卡因气雾剂是一种局部麻醉药物，主要用于治疗成年男性原发性早泄问题，临床疗效明确，使用方便。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","03347","BK1576","BK1141","301263","BK1583"],"gpt_icon":0},{"id":"2434683532","title":"泰恩康最新公告：全资子公司利多卡因丙胺卡因气雾剂收到药品注册临床试验受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2434683532","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434683532?lang=zh_cn&edition=full","pubTime":"2024-05-10 17:39","pubTimestamp":1715333988,"startTime":"0","endTime":"0","summary":"泰恩康公告，全资子公司利多卡因丙胺卡因气雾剂收到药品注册临床试验受理通知书。利多卡因丙胺卡因气雾剂是一种局部麻醉药物，主要用于治疗成年男性原发性早泄问题，临床疗效明确，使用方便。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000034591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK1576","BK1583","BK0250","BK1141","301263"],"gpt_icon":0},{"id":"2433717115","title":"华安证券：给予泰恩康买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2433717115","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433717115?lang=zh_cn&edition=full","pubTime":"2024-05-08 17:09","pubTimestamp":1715159395,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超,李昌幸近期对泰恩康进行研究并发布了研究报告《主营业务稳健发展，CKBA创新药临床进展顺利》，本报告对泰恩康给出买入评级，当前股价为14.79元。未来CKBA有望成为公司的另一重磅品种。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，买入评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800031005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600909","301263"],"gpt_icon":0},{"id":"2431722399","title":"泰恩康4月30日现1笔大宗交易 成交金额4218万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431722399","media":"智能小浪","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431722399?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:00","pubTimestamp":1714467600,"startTime":"0","endTime":"0","summary":"　　4月30日，泰恩康平收，收盘价为14.28元，发生1笔大宗交易，合计成交量300万股，成交金额4218万元。　　进一步统计，近3个月内该股累计发生5笔大宗交易，合计成交金额为1.27亿元。该股近5个交易日累计上涨8.10%，主力资金合计净流出153.95万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-04-30/doc-inatrchx0540021.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-04-30/doc-inatrchx0540021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2431395881","title":"4月30日泰恩康现4218万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2431395881","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431395881?lang=zh_cn&edition=full","pubTime":"2024-04-30 16:41","pubTimestamp":1714466491,"startTime":"0","endTime":"0","summary":"证券之星消息，4月30日泰恩康发生大宗交易，交易数据如下：大宗交易成交价格14.06元，相对当日收盘价折价1.54%，成交300万股，成交金额4218万元，买方营业部为国泰君安证券股份有限公司汕头金砂路证券营业部，卖方营业部为华泰证券股份有限公司深圳深南大道基金大厦证券营业部。近三个月该股共发生5笔大宗交易，合计成交9.35万手，折价成交5笔。截至2024年4月30日收盘，泰恩康报收于14.28元，上涨0.0%，换手率1.21%，成交量3.25万手，成交额4675.02万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000034737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2430270884","title":"泰恩康(301263.SZ)：甲巯咪唑片境内生产药品注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2430270884","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430270884?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:41","pubTimestamp":1714138867,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康 公告，公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局签发的甲巯咪唑片境内生产药品注册上市许可申请《受理通知书》。另外，甲巯咪唑片还可用于甲状腺功能亢进症患者在使用放射性碘治疗前的准备用药，可以用于预防治疗后患者发生甲状腺毒性危象。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2430291298","title":"泰恩康上市次年营收净利齐降 医药代理板块贡献过半营收财报提示风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2430291298","media":"中国网财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430291298?lang=zh_cn&edition=full","pubTime":"2024-04-26 10:31","pubTimestamp":1714098660,"startTime":"0","endTime":"0","summary":"中国网财经4月26日讯 泰恩康上市次年业绩滑坡。日前，泰恩康发布2023年报。泰恩康最早由医药代理起家，经过多年发展，医药代理板块仍是公司收入和利润的主要来源。2023年，医药代理板块实现营收4.3亿元，在营收中的占比超过50%。对此，泰恩康在年报中也提示了代理业务的风险，尤其是公司作为沃丽汀在中国的唯一总代理，如果代理关系中止或终止，将对公司的经营产生重大不利影响。近1年，泰恩康的股价已下跌近30%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-26/doc-inatcmza6917993.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-26/doc-inatcmza6917993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301263"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-03-29","address":"广东省汕头市龙湖区泰山北路万吉南二街8号A幢","stockEarnings":[{"period":"1week","weight":-0.0062},{"period":"1month","weight":-0.0734},{"period":"3month","weight":-0.118},{"period":"6month","weight":-0.2492},{"period":"1year","weight":-0.3382},{"period":"ytd","weight":-0.1931}],"companyName":"广东泰恩康医药股份有限公司","boardCode":"AI0051","perCapita":"21774股","boardName":"批发业","registeredCapital":"42549万元","compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":-0.028},{"period":"3month","weight":-0.0072},{"period":"6month","weight":0.0306},{"period":"1year","weight":-0.0677},{"period":"ytd","weight":0.0194}],"survey":"　　广东泰恩康医药股份有限公司主营业务为代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品包括处方药、OTC、医疗器械、卫生材料、医药技术服务等。","serverTime":1718601415991,"listedPrice":19.93,"stockholders":"12294人(较上一季度减少4.56%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰恩康,301263,泰恩康股票,泰恩康股票老虎,泰恩康股票老虎国际,泰恩康行情,泰恩康股票行情,泰恩康股价,泰恩康股市,泰恩康股票价格,泰恩康股票交易,泰恩康股票购买,泰恩康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}